Antimicrobial resistance in Neisseria gonorrhoeae and Mycoplasma genitalium: a narrative review of diagnosis, resistance detection, and clinical management
Intisari Sains Medis · 09.11.2026 · 17 (3)
DOI: 10.15562/ism.v17i3.2837 ↗Kurz gefasst
Fachartikel in der Zeitschrift Intisari Sains Medis, online erschienen am 09.11.2026. Verfasst von Desak Putu Sukasanti Adi Kunti und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction
Antimicrobial resistance has narrowed the treatment of bacterial sexually transmitted infections, and Neisseria gonorrhoeae and Mycoplasma genitalium follow contrasting resistance trajectories. Gonococcal resistance is acquired and spans several antimicrobial classes, whereas M. genitalium combines intrinsic insusceptibility to cell-wall agents with acquired macrolide and fluoroquinolone resistance. This review compares both organisms across diagnosis, resistance detection, and clinical management.
Methods
PubMed/MEDLINE, PubMed Central, Scopus, ScienceDirect, and Google Scholar were searched together with the WHO, CDC, and FDA repositories, with a final search date of 20 September 2026. English-language publications from January 2016 to September 2026 were eligible, comprising guidelines, regulatory labels, phase 3 trials, systematic reviews, surveillance reports, and laboratory or observational studies. Evidence was synthesized thematically in four priority tiers without statistical pooling.
Results
Gonococcal resistance involves penA-mediated target alteration, reduced porin permeability, MtrCDE efflux, gyrA and parC mutations, and plasmid-mediated determinants, so molecular assays predict rather than confirm susceptibility, and culture retains a role. In M. genitalium, 23S rRNA mutations predict macrolide failure reliably, whereas parC and gyrA mutations differ in predictive value. Ceftriaxone remains the recommended treatment for gonorrhoea, with WHO and CDC differing in dose and test-of-cure indications, and sequential doxycycline-based regimens remain resistance-guided for M. genitalium. Gepotidacin and zoliflodacin were approved in the United States in December 2025 for uncomplicated urogenital infection only, under differing restrictions.
Conclusion
Within the limits of a narrative synthesis without formal certainty assessment, treatment selection depends on organism, anatomical site, available resistance information, local epidemiology, and regulatory availability.
Zitieren
APA
Kunti, D. P. S. A., Winaya, K. K., & Mahardika, M. B. B. (2026). Antimicrobial resistance in Neisseria gonorrhoeae and Mycoplasma genitalium: a narrative review of diagnosis, resistance detection, and clinical management. Intisari Sains Medis, 17(3). https://doi.org/10.15562/ism.v17i3.2837
Vancouver
Kunti DPSA, Winaya KK, Mahardika MBB. Antimicrobial resistance in Neisseria gonorrhoeae and Mycoplasma genitalium: a narrative review of diagnosis, resistance detection, and clinical management. Intisari Sains Medis. 2026;17(3). doi:10.15562/ism.v17i3.2837
BibTeX
@article{Kunti2026,
author = {Kunti, Desak Putu Sukasanti Adi and Winaya, Ketut Kwartantaya and Mahardika, Made Bagus Basuki},
title = {Antimicrobial resistance in Neisseria gonorrhoeae and Mycoplasma genitalium: a narrative review of diagnosis, resistance detection, and clinical management},
journal = {Intisari Sains Medis},
year = {2026},
volume = {17},
number = {3},
doi = {10.15562/ism.v17i3.2837}
}
EUVIMED